(Q34950123)

5 August 2017

1 reference

title

Pulmonary arterial hypertension in congenital heart disease. (English)

1 reference

5 August 2017

0 references

arterial hypertension

1 reference

John T Granton

1

1 reference

5 August 2017

Marlene Rabinovitch

series ordinal

2

1 reference

5 August 2017

publication date

1 August 2002

1 reference

5 August 2017

1 reference

5 August 2017

volume

20

1 reference

5 August 2017

issue

3

1 reference

5 August 2017

page(s)

441-57, vii

1 reference

The Eisenmenger syndrome in adults

5 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2802%2900017-6

7 January 2021

The Eisenmenger syndrome or pulmonary hypertension with reversed central shunt. I.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2802%2900017-6

7 January 2021

Fate of the patient with the eisenmenger syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2802%2900017-6

7 January 2021

Isolated atrial septal defect with pulmonary vascular obstructive disease--long-term follow-up and prediction of outcome after surgical correction.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2802%2900017-6

7 January 2021

Primary pulmonary hypertension. A national prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2802%2900017-6

7 January 2021

Determinants of survival and length of survival in adults with Eisenmenger syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2802%2900017-6

7 January 2021

Prognosis for patients with ventricular septal defect and severe pulmonary vascular obstructive disease

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2802%2900017-6

7 January 2021

Prognosis for patients with Eisenmenger syndrome of various aetiology

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2802%2900017-6

7 January 2021

Eisenmenger syndrome. Factors relating to deterioration and death

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2802%2900017-6

7 January 2021

Severe pulmonary hypertension without right ventricular failure: the unique hearts of patients with Eisenmenger syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2802%2900017-6

7 January 2021

Primary pulmonary hypertension. Length of survival in patients referred for heart-lung transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2802%2900017-6

7 January 2021

Factors that influence the outcome of primary pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2802%2900017-6

7 January 2021

Role of atrial septostomy in the treatment of pulmonary vascular disease

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2802%2900017-6

7 January 2021

Graded balloon dilation atrial septostomy in severe primary pulmonary hypertension. A therapeutic alternative for patients nonresponsive to vasodilator treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2802%2900017-6

7 January 2021

Systemic oxygen transport in patients with congenital heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2802%2900017-6

7 January 2021

Pathobiology of pulmonary hypertension: Impact on clinical management

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2802%2900017-6

7 January 2021

Lung biopsy in congenital heart disease: a morphometric approach to pulmonary vascular disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2802%2900017-6

7 January 2021

The pathology of hypertensive pulmonary vascular disease; a description of six grades of structural changes in the pulmonary arteries with special reference to congenital cardiac septal defects

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2802%2900017-6

7 January 2021

Vascular structure in lung tissue obtained at biopsy correlated with pulmonary hemodynamic findings after repair of congenital heart defects.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2802%2900017-6

7 January 2021

Endothelial cell-derived heparan sulfate binds basic fibroblast growth factor and protects it from proteolytic degradation

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2802%2900017-6

7 January 2021

Human mast cell chymase and leukocyte elastase release latent transforming growth factor-beta 1 from the extracellular matrix of cultured human epithelial and endothelial cells

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2802%2900017-6

7 January 2021

Tenascin-C is induced with progressive pulmonary vascular disease in rats and is functionally related to increased smooth muscle cell proliferation

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2802%2900017-6

7 January 2021

Fibronectin, hyaluronan, and a hyaluronan binding protein contribute to increased ductus arteriosus smooth muscle cell migration

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2802%2900017-6

7 January 2021

Microtubule-associated protein 1 light chain 3 is a fibronectin mRNA-binding protein linked to mRNA translation in lamb vascular smooth muscle cells

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2802%2900017-6

7 January 2021

Complete reversal of fatal pulmonary hypertension in rats by a serine elastase inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2802%2900017-6

7 January 2021

Enhanced expression of vascular endothelial growth factor in pulmonary plexogenic arteriopathy due to congenital heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2802%2900017-6

7 January 2021

The pathobiology of pulmonary hypertension. Endothelium

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2802%2900017-6

7 January 2021

Circulating endothelin in children with congenital heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2802%2900017-6

7 January 2021

An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2802%2900017-6

7 January 2021

Expression of endothelin-1 in the lungs of patients with pulmonary hypertension.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2802%2900017-6

7 January 2021

Nitric oxide and endothelin-1 in pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2802%2900017-6

7 January 2021

Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2802%2900017-6

7 January 2021

ET(A) and ET(B) receptors modulate the proliferation of human pulmonary artery smooth muscle cells

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2802%2900017-6

7 January 2021

Increased plasma endothelin-1 in pulmonary hypertension: marker or mediator of disease?

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2802%2900017-6

7 January 2021

Inhaled nitric oxide inhibits human platelet aggregation, P-selectin expression, and fibrinogen binding in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2802%2900017-6

7 January 2021

Decreased nitric oxide in the exhaled air of patients with systemic sclerosis with pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2802%2900017-6

7 January 2021

Exhaled nitric oxide and pulmonary response to iloprost in systemic sclerosis with pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2802%2900017-6

7 January 2021

High expression of endothelial nitric oxide synthase in plexiform lesions of pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2802%2900017-6

7 January 2021

Altered arterial expression patterns of inducible and endothelial nitric oxide synthase in pulmonary plexogenic arteriopathy caused by congenital heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2802%2900017-6

7 January 2021

Sustained Increase in Aortic Endothelial Nitric Oxide Synthase Expression In Vivo in a Model of Chronic High Blood Flow

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2802%2900017-6

7 January 2021

Ontogeny of nitric oxide in the pulmonary vasculature

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2802%2900017-6

7 January 2021

Impairment of endothelium-dependent pulmonary-artery relaxation in chronic obstructive lung disease

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2802%2900017-6

7 January 2021

The pathobiology of pulmonary hypertension. Smooth muscle cells and ion channels

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2802%2900017-6

7 January 2021

Dysfunctional voltage-gated K+ channels in pulmonary artery smooth muscle cells of patients with primary pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2802%2900017-6

7 January 2021

Upregulated TRP and enhanced capacitative Ca(2+) entry in human pulmonary artery myocytes during proliferation

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2802%2900017-6

7 January 2021

Sustained membrane depolarization and pulmonary artery smooth muscle cell proliferation.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2802%2900017-6

7 January 2021

High K(+)-induced membrane depolarization attenuates endothelium-dependent pulmonary vasodilation

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2802%2900017-6

7 January 2021

Inhibition of K(+) channel activity in human pulmonary artery smooth muscle cells by serum from patients with pulmonary hypertension secondary to congenital heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2802%2900017-6

7 January 2021

Monoclonal endothelial cell proliferation is present in primary but not secondary pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2802%2900017-6

7 January 2021

Expression of angiogenesis-related molecules in plexiform lesions in severe pulmonary hypertension: evidence for a process of disordered angiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2802%2900017-6

7 January 2021

Microsatellite instability of endothelial cell growth and apoptosis genes within plexiform lesions in primary pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2802%2900017-6

7 January 2021

Fine mapping of PPH1, a gene for familial primary pulmonary hypertension, to a 3-cM region on chromosome 2q33

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2802%2900017-6

7 January 2021

Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2802%2900017-6

7 January 2021

Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2802%2900017-6

7 January 2021

Sporadic primary pulmonary hypertension is associated with germline mutations of the gene encoding BMPR-II, a receptor member of the TGF-beta family

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2802%2900017-6

7 January 2021

Bone morphogenetic proteins, genetics and the pathophysiology of primary pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2802%2900017-6

7 January 2021

Mutation in the gene for bone morphogenetic protein receptor II as a cause of primary pulmonary hypertension in a large kindred

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2802%2900017-6

7 January 2021

Altered growth responses of pulmonary artery smooth muscle cells from patients with primary pulmonary hypertension to transforming growth factor-beta(1) and bone morphogenetic proteins

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2802%2900017-6

7 January 2021

Genomic approaches to research in pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2802%2900017-6

7 January 2021

Gene expression patterns in the lungs of patients with primary pulmonary hypertension: a gene microarray analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2802%2900017-6

7 January 2021

Oxygen therapy improves cardiac index and pulmonary vascular resistance in patients with pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2802%2900017-6

7 January 2021

Effect of body position changes on pulmonary gas exchange in Eisenmenger's syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2802%2900017-6

7 January 2021

Nocturnal oxygen therapy in patients with the Eisenmenger syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2802%2900017-6

7 January 2021

Long-term treatment of primary pulmonary hypertension with continuous intravenous epoprostenol (prostacyclin)

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2802%2900017-6

7 January 2021

Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2802%2900017-6

7 January 2021

A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2802%2900017-6

7 January 2021

Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2802%2900017-6

7 January 2021

Differential effects of stable prostacyclin analogs on smooth muscle proliferation and cyclic AMP generation in human pulmonary artery

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2802%2900017-6

7 January 2021

Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2802%2900017-6

7 January 2021

Compassionate use of continuous prostacyclin in the management of secondary pulmonary hypertension: a case series

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2802%2900017-6

7 January 2021

Effect of orally active prostacyclin analogue on survival of outpatients with primary pulmonary hypertension.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2802%2900017-6

7 January 2021

Selective pulmonary vasodilation by inhaled prostacyclin in a newborn with congenital heart disease and cardiopulmonary bypass

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2802%2900017-6

7 January 2021

Long-Term Treatment of Primary Pulmonary Hypertension with Aerosolized Iloprost, a Prostacyclin Analogue

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2802%2900017-6

7 January 2021

Inhaled nitric oxide in full-term and nearly full-term infants with hypoxic respiratory failure

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2802%2900017-6

7 January 2021

In vitro comparison of two NONOates (novel nitric oxide donors) on rat pulmonary arteries

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2802%2900017-6

7 January 2021

Aerosolized soluble nitric oxide donor improves oxygenation and pulmonary hypertension in acute lung injury.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2802%2900017-6

7 January 2021

Nitric oxide- and nitric oxide donors-induced relaxation and its modulation by oxidative stress in piglet pulmonary arteries

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2802%2900017-6

7 January 2021

Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2802%2900017-6

7 January 2021

Cell-based gene transfer to the pulmonary vasculature: Endothelial nitric oxide synthase overexpression inhibits monocrotaline-induced pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2802%2900017-6

7 January 2021

Cell-based gene transfer of vascular endothelial growth factor attenuates monocrotaline-induced pulmonary hypertension.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2802%2900017-6

7 January 2021

The Registry of the International Society for Heart and Lung Transplantation: eighteenth Official Report-2001.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2802%2900017-6

7 January 2021

Heart-lung or lung transplantation for Eisenmenger syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2802%2900017-6

7 January 2021

Lung and heart-lung transplant practice patterns in pulmonary hypertension centers

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2802%2900017-6

7 January 2021

Assessment of survival benefit after lung transplantation by patient diagnosis

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2802%2900017-6

7 January 2021

10.1016/S0733-8651(02)00017-6

Identifiers

DOI

1 reference

5 August 2017

1 reference